At a glance
ClinicalIndex Comparison RecordPhase 2Unknown· 120 target
Drug / intervention
RC48-ADCdrug
Likely dose
RC48-ADC 2.0mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open, Multi-cohort, Multi-center Phase II Basket Clinical Study of RC48-ADC Monotherapy in the Treatment of HER2-expressing (HER2-positive and HER2 Low Expression) Gynecological Malignancies
In Brief
A Phase 2 clinical trial evaluating RC48-ADC for Gynecological Malignancy. Targeting 120 participants across 1 site.
Detailed Summary
This study will evaluate the effectiveness and safety of intravenous injection of RC48-ADC in the treatment of HER2 expression (HER2 positive and HER2 low expression) gynecological malignancies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGynecological Malignancy
CountriesChina
Collaborators--
Timeline
Phase 2UnknownOverdue
20222023202420252026
First PostedJul 2021
Enrollment StartDec 2021
Primary CompletionOct 2024
Study CompletionJun 2025
TodayJul 2026
First PostedJul 16, 2021
Enrollment StartDec 21, 2021
Primary CompletionOct 1, 2024
Study CompletionJun 1, 2025
TodayJul 1, 2026
Enrollment to primary: 2.8 yearsPosted 5.0 years ago
Interventions
RC48-ADCdrug
2.0mg/kg IV every 2 weeks